1. Home
  2. OMER vs IGIC Comparison

OMER vs IGIC Comparison

Compare OMER & IGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Omeros Corporation

OMER

Omeros Corporation

N/A

Current Price

$13.29

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Logo International General Insurance Holdings Ltd.

IGIC

International General Insurance Holdings Ltd.

N/A

Current Price

$23.89

Market Cap

996.3M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
OMER
IGIC
Founded
1994
2001
Country
United States
Jordan
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
996.3M
IPO Year
2008
2019

Fundamental Metrics

Financial Performance
Metric
OMER
IGIC
Price
$13.29
$23.89
Analyst Decision
Buy
Buy
Analyst Count
3
2
Target Price
$27.50
★ $30.00
AVG Volume (30 Days)
★ 1.2M
64.4K
Earning Date
11-16-2026
11-03-2026
Dividend Yield
N/A
★ 6.08%
EPS Growth
★ 98.15
N/A
EPS
★ 0.13
N/A
Revenue
★ $29,868,000.00
N/A
Revenue This Year
N/A
$4.98
Revenue Next Year
$66.13
$2.89
P/E Ratio
$107.77
★ $9.05
Revenue Growth
N/A
★ N/A
52 Week Low
$6.70
$22.14
52 Week High
$21.24
$29.59

Technical Indicators

Market Signals
Indicator
OMER
IGIC
Relative Strength Index (RSI) 30.78 43.85
Support Level $9.45 $23.18
Resistance Level $19.68 $25.24
Average True Range (ATR) 0.92 0.69
MACD -0.45 0.02
Stochastic Oscillator 8.90 33.76

Price Performance

Historical Comparison
OMER
IGIC

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

About IGIC International General Insurance Holdings Ltd.

International General Insurance Holdings Ltd is an international specialty insurance and reinsurance group. It underwrites a diversified portfolio of specialty risks including energy, property, construction and engineering, ports and terminals, general aviation, political violence, professional lines, financial institutions, marine, contingency and treaty reinsurance. The company's operating segments include Specialty Longtail, Specialty Short tail and Reinsurance. The majority of revenue is derived from the Specialty Short-tail segment, which comprises business lines with underwriting risks assumed in the form of property and specialty lines insurance and of short-term nature with respect to related claims.

Share on Social Networks: